Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: Publication

    Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma

    C Ottensmeier, et al. ASCO 2023 Abstract available on the ASCO website – Download the abstract here Poster Presentation

    Published 26 May 2023
    Categorized as 2023, Myvac, Publication, TG4050

    Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M)  anogenital cancers

    C. Le Tourneau, et al. ASCO 2023 Abstract available on the ASCO website – Download the abstract here Poster Presentation

    Published 26 May 2023
    Categorized as 2023, Publication, TG4001

    Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy

    H. Le et al.AACR 2023Download the poster herePoster Presentation

    Published 19 April 2023
    Categorized as 2023, Invir.IO, Publication

    PoxSTG, a novel chimeric poxvirus with improved oncolytic potency

    P Erbs et al.AACR 2023Download the poster herePoster Presentation

    Published 19 April 2023
    Categorized as 2023, Invir.IO, Publication

    Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer

    A. Samson et al.AACR 2023Download the poster herePoster Presentation

    Published 18 April 2023
    Categorized as 2023, Publication, TG6002, TG6002

    Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

    A. Lalane et al.AACR 2023Download the poster herePoster Presentation

    Published 18 April 2023
    Categorized as 2023, Myvac, Publication, TG4050

    A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers

    C. Le Tourneau et al.AACR 2023Download the poster herePoster Presentation

    Published 17 April 2023
    Categorized as 2023, Publication, TG4001

    Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators

    JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

    Published 17 April 2023
    Categorized as 2023, Invir.IO, Publication

    TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses

    JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

    Published 16 April 2023
    Categorized as 2023, Invir.IO, Publication, publication HP en, TG6050-en

    Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses

    L. Walther et al.AACR 2023Download the poster herePoster Presentation

    Published 16 April 2023
    Categorized as 2023, Publication

    Posts navigation

    Page 1 … Page 10 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo